FDA grants accelerated approval for Tarpeyo to reduce proteinuria in IgA nephropathy.
This indication is approved under accelerated approval. It has not been established whether Tarpeyo slows kidney function decline in patients with IgAN. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. This approval marks the successful transition for Calliditas to a commercial-stage biopharmaceutical company.
Tarpeyo is approved under accelerated approval based on achieving its primary endpoint of reduction in proteinuria in Part A of the NeflgArd pivotal Phase III study, an ongoing, randomized, double-blind, placebo-controlled, multicenter study conducted to evaluate the efficacy and safety of Tarpeyo 16 mg once daily vs placebo in adult patients with primary IgAN. The effect of Tarpeyo was assessed in patients with biopsy-proven IgAN, eGFR greater than 35 mL/min/1.73 m2, and proteinuria (defined as either greater than 1 g/day or UPCR greater than 0.8 g/g) who were on a stable dose of maximally-tolerated RAS inhibitor therapy.
Patients taking Tarpeyo (n=97) showed a statistically significant 34% reduction in proteinuria from baseline vs 5% with RASi alone (n=102) at 9 months. The treatment effects for the primary endpoint of UPCR at 9 months were consistent across key subgroups, including key demographic and baseline disease characteristics.
Richard Lafayette M.D., Professor of Medicine at Stanford University and the Director of the Stanford Glomerular Disease Center commented, “IgAN is a tough diagnosis for many patients, and it can progressively lead to the need for dialysis and/or kidney transplantation. The FDA approval of Tarpeyo now offers disease-specific treatment for patients with this complicated disease.”
Related news and insights
Sorrento Therapeutics, Inc. announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase IIA randomised, placebo-controlled study of intravenous allogenic adipose-derived mesenchymal stromal cells to treat Post COVID 19 "Long Haul" Pulmonary compromise (NCT04992247).
Amryt presents long-term safety and efficacy data from the open-label extension (OLE) of its global Phase III MPOWERED non-inferiority clinical trial that compared Mycapssa (oral octreotide capsules) to long-acting iSRLs (injectable Somatostatin Receptor Ligands) for maintenance of biochemical response in patients with acromegaly.
Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment.